BriaCell Therapeutics Corp.
BCTX · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $37 | $36 | $38 | $38 |
| Gross Profit | -$37 | -$36 | -$38 | -$38 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,242 | $9,717 | $6,843 | $8,189 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,269 | $1,937 | $2,122 | $2,100 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,511 | $11,653 | $8,965 | $10,289 |
| Operating Income | -$11,548 | -$11,690 | -$9,003 | -$10,328 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $62 | $533 | $147 | $1,198 |
| Pre-Tax Income | -$11,487 | -$11,157 | -$8,856 | -$9,130 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,375 | -$11,057 | -$8,717 | -$9,063 |
| % Margin | – | – | – | – |
| EPS | -4.31 | -5.87 | -23.33 | -33.57 |
| % Growth | 26.6% | 74.8% | 30.5% | – |
| EPS Diluted | -4.31 | -5.87 | -23.33 | -33.57 |
| Weighted Avg Shares Out | 1,884 | 1,884 | 1,868 | 2,700 |
| Weighted Avg Shares Out Dil | 1,884 | 1,884 | 1,868 | 2,700 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $46 | $38 | $67 |
| Interest Expense | $0 | $0 | $53 | $0 |
| Depreciation & Amortization | $37 | $36 | $38 | $38 |
| EBITDA | -$11,450 | -$11,120 | -$8,766 | -$9,091 |
| % Margin | – | – | – | – |